Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 102Carcinoma, Intraductal, Noninfiltrating 12Breast Carcinoma In Situ 10Ovarian Neoplasms 6Neoplasm Metastasis 6Breast Neoplasms, Male 6Neoplasms 5Glioblastoma 5Central Nervous System Neoplasms 5Prostatic Neoplasms 4Gliosarcoma 4Inflammatory Breast Neoplasms 3Glioma 3Brain Neoplasms 3Astrocytoma 3Urinary Bladder Neoplasms 2Pancreatic Neoplasms 2Oligodendroglioma 2Glioma, Subependymal 2Fallopian Tube Neoplasms 2Ependymoma 2Breast Cancer Female 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Sarcoma 1Risk Reduction Behavior 1

Interventions

Magnetic Resonance Spectroscopy 3Specimen Handling 2Biopsy 2radium Ra 223 dichloride 1pembrolizumab 1binimetinib 1abemaciclib 1X-Rays 1Vorinostat 1Taxes 1Tamoxifen 1Steroids 1Photons 1Paclitaxel 1Letrozole 1Imatinib Mesylate 1Hormones 1Fulvestrant 1Cyclin-Dependent Kinase Inhibitor p18 1Cyclin-Dependent Kinase Inhibitor p16 1Capecitabine 116-fluoroestradiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Anatomic Stage IV Breast Cancer AJCC v8 × Tamoxifen × Clear all
NCT04190056 2023-08-31

Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer

University of California, San Francisco

Phase 2 Terminated
1 enrolled 4 charts
Breast

Anatomic Stage IV Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡